These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 11297603)

  • 21. [Low-density lipoprotein apheresis in familial hypercholesterolemia resistant to intensive medical treatment].
    Arbona C; Martinez-Hervás S; Goterris R; Montoro J; Real JT; Ascaso JF
    Med Clin (Barc); 2013 Mar; 140(5):207-10. PubMed ID: 22571847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low density lipoprotein kinetics in a family having defective low density lipoprotein receptors in which hypercholesterolemia is suppressed.
    Vega GL; Hobbs HH; Grundy SM
    Arterioscler Thromb; 1991; 11(3):578-85. PubMed ID: 2029498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis.
    Kawashiri MA; Nohara A; Higashikata T; Tada H; Nakanishi C; Okada H; Konno T; Sakata K; Hayashi K; Inazu A; Mabuchi H; Yamagishi M
    Atherosclerosis; 2017 Oct; 265():225-230. PubMed ID: 28926730
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased production of VLDL apoB-100 in subjects with familial hypercholesterolemia carrying the same null LDL receptor gene mutation.
    Tremblay AJ; Lamarche B; Ruel IL; Hogue JC; Bergeron J; Gagné C; Couture P
    J Lipid Res; 2004 May; 45(5):866-72. PubMed ID: 14967814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proportion of oxidized LDL relative to plasma apolipoprotein B does not change during statin therapy in patients with heterozygous familial hypercholesterolemia.
    van Tits LJ; van Himbergen TM; Lemmers HL; de Graaf J; Stalenhoef AF
    Atherosclerosis; 2006 Apr; 185(2):307-12. PubMed ID: 16005883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications.
    Watts GF; Cummings MH; Umpleby M; Quiney JR; Naoumova R; Thompson GR; Sönksen PH
    Eur J Clin Invest; 1995 Aug; 25(8):559-67. PubMed ID: 7589011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The metabolism of very low density and intermediate density lipoproteins in patients with familial hypercholesterolaemia.
    Soutar AK; Myant NB; Thompson GR
    Atherosclerosis; 1982 Jun; 43(2-3):217-31. PubMed ID: 7115461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute and long-term effects of low-density lipoprotein (LDL)-apheresis on oxidative damage to LDL and reducing capacity of erythrocytes in patients with severe familial hypercholesterolaemia.
    Stefanutti C; Di Giacomo S; Vivenzio A; Isacchi GC; Masella R; Caprari P; Varì R; Tarzia A; Mosiello A; Cantafora A
    Clin Sci (Lond); 2001 Feb; 100(2):191-8. PubMed ID: 11171288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term effects of LDL apheresis in patients with severe hypercholesterolemia.
    Sachais BS; Katz J; Ross J; Rader DJ
    J Clin Apher; 2005 Dec; 20(4):252-5. PubMed ID: 15880364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-density lipoprotein levels and not mutation status predict intima-media thickness in familial hypercholesterolemia.
    Fahed AC; Habib RH; Nemer GM; Azar ST; Andary RR; Arabi MT; Moubarak EM; Bitar FF; Haddad FF
    Ann Vasc Surg; 2014 Feb; 28(2):421-6. PubMed ID: 24120234
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-density lipoprotein (LDL) oxidizability before and after LDL apheresis.
    Donner MG; Parhofer KG; Richter WO; Schwandt P
    Metabolism; 1999 Jul; 48(7):881-6. PubMed ID: 10421230
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma markers of cholesterol homeostasis and apolipoprotein B-100 kinetics in the metabolic syndrome.
    Chan DC; Watts GF; Barrett PH; O'Neill FH; Thompson GR
    Obes Res; 2003 Apr; 11(4):591-6. PubMed ID: 12690090
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo metabolism of ApoB, ApoA-I, and VLDL triglycerides in a form of hypobetalipoproteinemia not linked to the ApoB gene.
    Elias N; Patterson BW; Schonfeld G
    Arterioscler Thromb Vasc Biol; 2000 May; 20(5):1309-15. PubMed ID: 10807747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
    Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH
    J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Altered metabolism of low-density lipoprotein and very-low-density lipoprotein remnant in autosomal recessive hypercholesterolemia: results from stable isotope kinetic study in vivo.
    Tada H; Kawashiri MA; Ikewaki K; Terao Y; Noguchi T; Nakanishi C; Tsuchida M; Takata M; Miwa K; Konno T; Hayashi K; Nohara A; Inazu A; Kobayashi J; Mabuchi H; Yamagishi M
    Circ Cardiovasc Genet; 2012 Feb; 5(1):35-41. PubMed ID: 22157599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol--the role of LDL-apheresis.
    McGowan MP
    J Clin Lipidol; 2013; 7(3 Suppl):S21-6. PubMed ID: 23642325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Small, dense high-density lipoprotein 3 particles exhibit defective antioxidative and anti-inflammatory function in familial hypercholesterolemia: Partial correction by low-density lipoprotein apheresis.
    Hussein H; Saheb S; Couturier M; Atassi M; Orsoni A; Carrié A; Therond P; Chantepie S; Robillard P; Bruckert E; Chapman MJ; Kontush A
    J Clin Lipidol; 2016; 10(1):124-33. PubMed ID: 26892129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Delayed low density lipoprotein (LDL) catabolism despite a functional intact LDL-apolipoprotein B particle and LDL-receptor in a subject with clinical homozygous familial hypercholesterolemia.
    Schmidt HH; Stuhrmann M; Shamburek R; Schewe CK; Ebhardt M; Zech LA; Büttner C; Wendt M; Beisiegel U; Brewer HB; Manns MP
    J Clin Endocrinol Metab; 1998 Jun; 83(6):2167-74. PubMed ID: 9626156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetics and kinetics of familial hypercholesterolemia, with the special focus on FH-(Marburg) p.W556R.
    Soufi M; Kurt B; Schweer H; Sattler AM; Klaus G; Zschocke J; Schaefer JR
    Atheroscler Suppl; 2009 Dec; 10(5):5-11. PubMed ID: 20129366
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased clearance of low density lipoprotein precursors in patients with heterozygous familial defective apolipoprotein B-100: a stable isotope approach.
    Pietzsch J; Wiedemann B; Julius U; Nitzsche S; Gehrisch S; Bergmann S; Leonhardt W; Jaross W; Hanefeld M
    J Lipid Res; 1996 Oct; 37(10):2074-87. PubMed ID: 8906585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.